Key Highlights

  • New Collaboration: BrainsWay has entered a strategic Partnership with Mindful Health Solutions, whose Parent Company Radial Health operates the largest US network of brain medicine clinics across 27 locations in seven states.
  • Technology Deployment: The agreement covers deployment of BrainsWay's Deep TMS system and the recently FDA-cleared SWIFT accelerated treatment protocol at partner clinics.
  • Education Initiative: Both companies plan to build joint physician education programs, including key opinion leader events, clinical outreach, and research into synergistic treatment approaches.
  • Follow-On Investment: BrainsWay has also made an additional $0.8 million Equity Investment in the managed services organization that supports the Texas-based Heading Health clinic network.

BrainsWay Ltd.(NASDAQ:BWAY), a developer of noninvasive neurostimulation therapies for psychiatric conditions, has announced a strategic collaboration with Mindful Health Solutions, a behavioral health provider whose managed services operations were acquired earlier this year by Radial Health, Inc. The combined Radial-branded entity now supports the largest network of brain medicine clinics in the United States.

The Partnership and What It Covers

Mindful Health Solutions, now operating under the Radial banner following an August acquisition, manages 27 brain medicine clinic locations spread across California, Missouri, New York, South Carolina, Tennessee, Texas, and Washington. The collaboration with BrainsWay is intended to extend patient access to two key noninvasive treatment technologies: the company's Deep Transcranial Magnetic Stimulation platform, known as Deep TMS, and its recently cleared SWIFT protocol, which provides an accelerated treatment option for qualifying patients.

Additionally, the companies plan to explore whether Neurolief's Proliv Rx at-home neuromodulation therapy—a product in which BrainsWay has a strategic interest—can be woven into broader patient care pathways through the Radial clinical network. The arrangement creates a pathway for BrainsWay to move beyond pure device Placement and into deeper clinical integration with a partner that has both scale and operational expertise in brain medicine.

Strategic Alignment and Broader Ambitions

BrainsWay CEO Hadar Levy described the partnership as a natural fit, pointing to Mindful Health Solutions' standing as one of the country's leading organizations in brain medicine research and real-world clinical operations. The collaboration is explicitly designed to do two things at once: accelerate the adoption of existing treatments and identify new treatment approaches through joint clinical research.

This deal is not the only partnership-driven initiative BrainsWay has been advancing. Alongside the Mindful Health Solutions announcement, the company disclosed a follow-on equity investment of $0.8 million in the management services organization backing the Heading Health clinic network in Texas. These investments reflect a deliberate strategy: rather than relying solely on device sales, BrainsWay is embedding itself in the operational and financial infrastructure of clinical providers to drive long-term treatment volume.

Risks

BrainsWay's strategy of partnering with and investing in clinic network operators creates concentration risk. If any of its key partners face financial difficulties, regulatory setbacks, or operational disruptions, the Revenue and patient Volume BrainsWay has come to depend on through those relationships could be affected. The managed services organizations in this space have also seen significant corporate activity—the August Acquisition of Mindful Health Solutions' managed services arm by Radial Health is one example—and further consolidation or ownership changes could disrupt existing collaboration terms.

The clinical adoption of noninvasive brain stimulation therapies also depends heavily on insurance reimbursement policies. Any adverse changes to coverage for Deep TMS or related modalities could constrain growth, regardless of the quality of the underlying clinical evidence.

What to Watch Next

The success of the Mindful Health Solutions collaboration will likely hinge on how quickly BrainsWay can move from signed agreement to active deployment across Radial's 27 clinic locations. Investors will want to track whether the SWIFT protocol gains meaningful clinical traction through this channel and whether the research component of the partnership generates publishable data that could further validate the technology's use.

The Heading Health investment is relatively small in dollar terms, but it signals a pattern. If BrainsWay continues to take minority stakes in clinic operators, the cumulative exposure—and the potential upside or downside from those positions—could become a more significant Factor over time.

Sector Context

The interventional psychiatry market is experiencing growing interest from both clinical and commercial perspectives. Noninvasive brain stimulation therapies, particularly TMS, have gained FDA clearances across a widening range of indications in recent years. BrainsWay currently holds three FDA-cleared indications for its Deep TMS platform, covering major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Competing TMS companies are also building out their clinical partnerships, making the pace and depth of BrainsWay's network relationships an increasingly important competitive variable.